EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.305
https://www.valueinhealthjournal.com/article/S1098-3015(22)02509-8/fulltext
Title :
EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02509-8&doi=10.1016/j.jval.2022.09.305
First page :
Section Title :
Open access? :
No
Section Order :
12113